To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)
Status:
Completed
Trial end date:
2018-05-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability and pharmacokinetics (PK) of multiple IV doses of
FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) administered every 8 hours (q8h) in healthy adult
volunteers for 10 days.